samedan logo
 
 
spacer
home > ict > autumn 2017 > fastening pharmaceuticals
PUBLICATIONS
International Clinical Trials

Fastening Pharmaceuticals

As consumers increasingly embrace the more affordable nature of wearable devices – choosing to monitor their own health and wellbeing with gadgets such as FitBit or Jawbone – it is no surprise that the wearable device market is set to grow to Ł25 billion by 2019 (1). However, this wearable technology has also been widely adopted by other markets, and none more so than by the healthcare industry, which reportedly earned revenues of $5.1 billion in 2015, according to a recent report by Frost and Sullivan (2). This wearable devices market is set to continue to revolutionise the healthcare industry with estimates that it will reach over $18 billion by 2020 (3).

It has been widely reported that CROs can leverage this wearable device trend to enable easier remote patient monitoring, improved therapeutic outcomes and deeper insight into clinical studies. Alongside this, traditional outsourcing in the area of clinical trial data management is seeing notable increases in market concentration, while speciality service providers are experiencing unprecedented growth. The Tufts Center for the Study of Drug Development estimates that, since 2011, small niche or speciality service providers have enjoyed strong relative annual growth, approaching 10% (4).

However, the clinical trial process is known to be complex, painstaking and is often criticised for not being sufficiently patient-centric. Therefore, it makes sense to innovate in this area to ease the challenges, streamline the various activities and generate better patient engagement. One way to do this is via digital technology and mobile health (5).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Jeremy Wheeler, Head of Statistics at Quanticate, is an experienced statistician with over 25 years' experience, including over 10 years in the pharma industry. He has worked in all phases of drug development, with particular knowledge of clinical studies, early phase design and analysis, methodology/biomarker studies and pharmacogenomics. Jeremy has a strong background in epidemiology and observational studies. He has applied this knowledge to post-marketing studies, meta-analyses and clinical registry studies.
spacer
Jeremy Wheeler
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Charles River to Present Collaborative Methods at Neuroscience 2018

Charles River Laboratories International, Inc. (NYSE: CRL) today announced that its team of neuroscience drug discovery experts will present 26 scientific posters, both independently and collaboratively with clients, at Neuroscience 2018, the 48th annual meeting of the Society for Neuroscience (SfN). The meeting, which brings together more than 30,000 researchers from 80 countries, will take place from November 3-7, in San Diego, California.
More info >>

White Papers

Preparation of Pharmaceutical Samples for Metals Analysis

RSSL

There has been a lot of discussion regarding the methods of analysis for pharmaceutical products as we await the upcoming changes to both the EP and USP, relating to the analysis of metal impurities.
More info >>

 
Industry Events

Biotech Showcase™ 2019

7-9 January 2019, Hilton San Francisco Union Square

Biotech Showcase™ is an investor and networking conference devoted to providing private and small- and mid-cap biotechnology companies an opportunity to present to and meet with investors and biopharmaceutical executives during the course of one of the largest annual healthcare conferences that attracts investors and biopharmaceutical executives from around the world.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement